TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TAI · 6491.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Pegavision Corp.’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Pegavision Corp.’s forward annual dividend is NT$10.01 per share, paid annual. The forward yield is 2.39% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Pegavision Corp.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of NT$6.70. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pegavision Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pegavision Corporation manufactures and sells medical devices, and optical and precision instruments in Taiwan. It offers soft contact lenses. The company was founded in 2009 and is based in Taoyuan City, Taiwan. Pegavision Corporation is a subsidiary of Kinsus Interconnect Technology Corp.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | Apr 28, 2025 | NT$6.23+16.01% vs estimate | NT$1.59B-9.89% vs estimate |
|---|
| Q4 2024 | Feb 17, 2025 | NT$5.13-10.78% vs estimate | NT$1.79B-41.3% vs estimate |
|---|
| Q3 2024 | Oct 29, 2024 | NT$5.58-12.13% vs estimate | NT$1.66B-15.52% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$264.00-NT$5.00 (-1.86%)
Visco Vision Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.0% below the high.
NT$88.10-NT$0.40 (-0.45%)
Formosa Optical Technology Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.05% below the high.
NT$90.20-NT$1.20 (-1.31%)
St.Shine Optical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.19% below the high.
NT$69.00-NT$0.50 (-0.72%)
ICARES Medicus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 16.9% below the high.
NT$72.10-NT$0.40 (-0.55%)
Crystalvue Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 13.45% below the high.
